Figure 1.

Combined effect of RAB and chemotherapeutic agents in PCa cells. (A) Anti-proliferative effect of RAB in PCa cell lines. PC3 and Du145 cells were treated with different concentrations of RAB and cell viability was measured by MTT assay. *P<0.05 vs. respective RAB-untreated control groups. (B) Western blot analysis of cleavage of PARP in response to RAB treatment. GAPDH served as an internal control. (C and D) Anti-proliferative activity of RAB combined with different chemotherapeutic agents; (C) PC3 and (D) Du145 cells were simultaneously treated with 4 µM of RAB and indicated chemotherapeutic agents including CDDP (2 µg/ml), ADM (300 nM), VP-16 (20 µM), DTX (10 nM) and VCR (10 nM) for 48 h at 37°C. Cell viability was measured by a MTT assay. *P<0.05 vs. single treatment with different chemotherapeutic agents. PCa, prostate cancer; CDDP, cisplatin; ADM, doxorubicin; VP-16, etoposide; DTX, docetaxel; VCR, vincristine; PARP, poly adenosine 5′-adenosine diphosphate ribose polymerase; RAB, Retigeric acid B.